IRS finalizes new tax for medical devices in healthcare law

WASHINGTON Wed Dec 5, 2012 7:40pm EST

WASHINGTON (Reuters) - The U.S. Internal Revenue Service on Wednesday released final rules for a new tax on medical devices, products ranging from surgical sutures to knee replacement implants, that starts next year as part of President Barack Obama's 2010 healthcare law.

The 2.3-percent tax must be paid, effective after December 31, by device-makers on their gross sales. The tax is expected to raise $29 billion in government revenues through 2022.

Companies including Boston Scientific Corp, 3M Co and Kimberly-Clark Corp have been lobbying the U.S. Congress for a repeal of the tax.

A repeal bill passed the Republican-controlled U.S. House of Representatives in June, but it has not been voted on by the Democratic-controlled Senate.

"The excise tax is on the medical device manufacturers and importers (who) will now have access to 30 million new customers due to the health care law," Treasury Department spokeswoman Sabrina Siddiqui said in a statement.

Many medical devices that are sold over-the-counter - such eyeglasses, contact lenses and hearing aids - are exempt from the tax, as are prosthetics, the IRS said.

The tax applies mostly to devices used and implanted by medical professionals, including items as complex as pacemakers or as simple as tongue depressors.

Products sold for humanitarian reasons, such as experimental cancer treatment devices, are not exempt from the tax.

Some medical device companies are hoping to delay the tax's start date as part of a resolution of the "fiscal cliff" deadline at the end of the year involving many tax and spending measures, said Steve Ferguson, chairman of Cook Group Inc.

"We would like to be part of the punt," Ferguson said, referring to an extension of current tax policy into 2013.

In one potentially problematic aspect of the tax, companies selling dual-use products to medical and non-medical customers must pay the tax on those products, potentially putting them at a competitive disadvantage, said Lew Fernandez, a director at PricewaterhouseCoopers LLP and a former IRS official.

For example, it remains "an open question" when latex gloves come under the tax, he said.

(Reporting by Patrick Temple-West; Editing by Kevin Drawbaugh and Tim Dobbyn)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
CaptainFreon wrote:
I feel there is an important point to clarify about this article quote: “A repeal bill passed the Republican-controlled U.S. House of Representatives in June, but it has not been voted on by the Democratic-controlled Senate.” That quote is simply tap dancing around the facts. To be completely honest with the masses, the author should have stated the reason WHY the senate did not vote on it. —>Harry Reid shelved that House Bill, it never even saw the light of a committee.

Dec 05, 2012 8:58pm EST  --  Report as abuse
Quietly all the medical device manufacturers are meeting with their lawyers and accountants to devise means of avoiding this tax. They are bifurcating their businesses into “manufacturing” and “distributing”. The distributors pay no excise tax and will show all the income. The manufacturers will record minimal income. The only winners will be the lawyers and the accountants.

Dec 05, 2012 10:19pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.